SLE Flare Prediction via Multiplexed Biomarker Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing systemic lupus erythematosus (SLE) flares are inadequate as they rely on traditional biomarkers that are not early or sufficient biologic signals, leading to delayed recognition and treatment, resulting in frequent disease flares and organ damage.
Innovation Solution
A method involving the assessment of specific soluble inflammatory and regulatory mediators in blood or plasma samples, including cytokines, chemokines, TNFR superfamily members, and regulatory molecules, to identify pre-flare events in SLE patients by measuring elevated levels of innate, Th1, Th2, and Th17 cytokines, chemokines, and TNFR superfamily members, along with reduced levels of regulatory mediators.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional biomarkers are used for diagnosing SLE flares, then the diagnostic method is simple and widely available, but the detection timing is delayed and the diagnostic precision is insufficient
Solution Approach 1:
The patent segments the diagnostic process by dividing the biomarker panel into specific functional categories: inflammatory mediators (IL-6, TNF-α, IL-1β), regulatory mediators (IL-10, TGF-β), and Th17 pathway mediators (IL-17, IL-23). This segmentation allows for targeted detection of early flare signals while maintaining a manageable assessment framework that balances precision with clinical feasibility
Solution Approach 2:
The patent applies preliminary action by identifying and measuring biomarker changes that occur before clinical flare symptoms manifest. The method detects elevated inflammatory mediators and suppressed regulatory mediators in the pre-flare state, enabling early intervention before full-blown flares occur, thus improving detection timing without requiring overly complex diagnostic systems
2Loss of time
If traditional clinical instruments are used to assess disease activity, then the assessment method is established and reliable, but the treatment intervention is delayed and organ damage progresses
Solution Approach 1:
The patent implements feedback by establishing a biomarker profile that provides early warning signals of impending flares. By monitoring the balance between inflammatory mediators (IL-6, TNF-α) and regulatory mediators (IL-10, TGF-β), the system provides feedback about disease trajectory before clinical symptoms appear, allowing timely treatment adjustment and preventing organ damage while maintaining reliable detection through validated biomarker panels
Solution Approach 2:
The patent enables preliminary treatment intervention by detecting pre-flare states through biomarker changes. The method identifies elevated Th17 pathway mediators and suppressed regulatory mediators before clinical flares occur, providing a window for proactive treatment that reduces both time to intervention and risk of organ damage while maintaining diagnostic reliability through established biomarker assays
3Speed
If rapid treatment with steroids is administered during flares, then the disease activity is quickly controlled, but side effects increase and long-term prognosis worsens
Solution Approach 1:
The patent applies preliminary anti-action by detecting and treating pre-flare states before full-blown flares occur. By identifying biomarker changes (elevated IL-6, TNF-α, and Th17 mediators with suppressed IL-10 and TGF-β) in the early stage, the method enables proactive treatment that prevents severe flares from developing, thereby reducing the need for high-dose steroids and minimizing treatment side effects while still achieving rapid disease control when intervention is necessary
Solution Approach 2:
The patent enables preliminary intervention by providing early detection of flare precursors through biomarker monitoring. This allows treatment to be initiated in the pre-flare state, controlling disease activity before it reaches severe levels, thus reducing the intensity and duration of steroid therapy needed while maintaining effective disease control and improving long-term prognosis
4Loss of information
If comprehensive biomarker assessment is performed, then the understanding of disease mechanisms improves, but the cost and complexity of testing increases
Solution Approach 1:
The patent segments the comprehensive biomarker assessment into three distinct functional pathways: inflammatory mediators (IL-6, TNF-α, IL-1β), regulatory mediators (IL-10, TGF-β), and Th17 pathway mediators (IL-17, IL-23). This segmentation provides mechanistic insight into different aspects of SLE pathogenesis while organizing the testing into manageable modules that can be performed using standard multiplex assays, balancing information gain with testing complexity
Solution Approach 2:
The patent applies universality by utilizing a single multiplexed assay system that can simultaneously measure multiple biomarkers across different functional pathways. This multi-functional approach provides comprehensive mechanistic insight into inflammatory, regulatory, and Th17 pathways using one integrated testing platform, reducing overall complexity compared to performing separate assays for each biomarker while maintaining thorough mechanistic understanding
Data Source
AI summary
The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided.